Promensil is an over-the-counter phytoestrogen supplement, originally intended to treat menopause, which has been shown to decrease breast cancer proliferation. This project examined this effect of Promensil, based on the estrogen receptor beta (ER-B). Using T47D cells with a tetracycline tunable ER-B, a decrease in cell proliferation was observed, but with no correlation to ER-B. Rather, Promensil appeared to compete with 17B-estradiol for estrogen receptor alpha. For the future, the correlation between ER-a and the phytoestrogen components of Promensil should be studied.

• This report represents the work of one or more WPI undergraduate students submitted to the faculty as evidence of completion of a degree requirement. WPI routinely publishes these reports on its website without editorial or peer review.

Creator

• Wambach, Rachel M

Publisher

• Worcester Polytechnic Institute

Identifier

• E-project-042418-131825

Advisor

• Rulfs, Jill
• Buckholt, Michael Allan

Year

• 2018

Date created

• 2018-04-24

Resource type

• Major Qualifying Project

Major

• Biology & Biotechnology

Rights statement

• In Copyright